cyclosporine
cyclosporine: 7 clinical trials tracked.
cyclosporine evidence translation
What we can confirm
7 tracked trials
What it means
What to watch
Prepared research question
What is verified about cyclosporine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 1 study sponsors
Study sponsors
Clinical Trials (7)
Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeks
Primary endpoint: Primary Outcome
Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunction
Primary endpoint: Change in Meibomian Gland Expressibility Score
Ruxolitinib Based GVHD Prophylaxis Regimen for Older Adults Receiving Non-ATG Containing Non-Myeloablative Hematopoietic Cell Transplantation for Acquired Aplastic Anemia
Primary endpoint: Incidence of grades II-IV acute graft-versus-host disease (GVHD)
A Phase III Randomized Trial Comparing Unrelated Donor Bone Marrow Transplantation With Immune Suppressive Therapy for Newly Diagnosed Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
Primary endpoint: The primary endpoint of this trial is time from randomization to treatment failure or death from any cause.
A Phase 1, Open-Label, Drug Interaction Study to Investigate the Effect of Multiple Doses of Cyclosporine on the Pharmacokinetics of LY3502970 in Healthy Participants
Primary endpoint: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3502970
A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Matched Unrelated Donors in Patients With Advanced Hematologic Malignancies and Hematological Disorders
Primary endpoint: Neutrophil Engraftment - The Days Till ANC Recovery
Phase II Study of IV Busulfan Combined With 12 cGy of Fractionated Total Body Irradiation (FTBI) and Etoposide (VP-16) as a Preparative Regimen for Allogeneic Bone Marrow Transplantation for Patients With Advanced Hematological Malignancies
Primary endpoint: Overall Survival at 5 Years Post-Transplant.